

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

(Use as many sheets as necessary)

Shee

1

3

Complete if Known

Application Number	10/510,585
Filing Date	8 October 2004
First Named Inventor	Debra FLEENOR et al.
Art Unit	
Examiner Name	
Attorney Docket Number	2354 US F

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)			
RD		WO 03/027275 A1	04/03/2003	Alcon, Inc.	
RD		WO 03/092584 A2	11/13/2003	Alcon, Inc.	

Examiner Signature		Date Considered	
-------------------------------	--	----------------------------	--

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes at USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Comptroller for Petitions, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

10 RING PORTFOLIO 28 FEB 2005

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Substitute for form 1449/PTO					
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>					
Sheet	2	of	3	Attorney Docket Number	2354 US F

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
RD	B1	Bain, J., H. McLauchlan, et al., "The specificities of protein kinase inhibitors: an update" BIOCHEM J 371(Pt 1):199-204 (2003)	
NOT PROVIDED	B2	Bengtsson, "Incidence of manifest glaucoma," BR J OPHTHALMOL, vol 73, pp 483-487 (1989)	
RD	B3	Coghlan, M. P. et al., "Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription" CHEM BIOL 7(10):793-803 (2000)	
RD	B4	Cohen, P. and Frame, S., "The renaissance of GSK3" NAT REV MOL CELL BIOL 2(10):769-776 (2001)	
RD	B5	Davis, S. T. et al., "Prevention of chemotherapy-induced alopecia in rats by CDK inhibitors" SCIENCE 291(5501):134-137 (2001)	
RD	B6	Hardcastle, I. R. et al., "Designing inhibitors of cyclin-dependent kinases" ANNU REV PHARMACOL TOXICOL 42:325-348 (2002)	
RD	B7	Knockaert, M. et al., "Pharmacological inhibitors of cyclin-dependent kinases" TRENDS PHARMACOL SCI 23(9):417-425 (2002)	
RD	B8	Kothapalli, D. and Grotendorst, G.R., "CTGF modulates cell cycle progression in cAMP-arrested NRK fibroblasts" J CELL PHYSIOL 182(1):119-126 (2000)	
RD	B9	Leost, M. et al., "Paullones are potent inhibitors of glycogen synthase kinase-3beta and cyclin-dependent kinase 5/p25" EUR J BIOCHEM 267(19):5983-5994 (2000)	
RD	B10	Leske MC, et al., AMERICAN JOURNAL OF EPIDEMIOLOGY, 118(2):166-191 (Aug 1983)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.88. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

10 Dec 2004

28 FEB 2005

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

3

of

3

Application Number

10/510,585

Filing Date

8 October 2004

First Named Inventor

Debra FLEENOR et al.

Art Unit

Examiner Name

2354 US F

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
RD	C1	Park, S. K., Kim, J., Seomun, Y., Choi, J., Kim, D. H., Han, I. O., Lee, E. H., Chung, S. K., Joo, C. K., "Hydrogen Peroxide is a Novel Inducer of Connective Tissue Growth Factor," Biochem. Biophys. Res. Commun. 284(4):966-971 (2001)	
	C2	Schwab, J. M., Postier, E., Nguyen, T. D., Mittelbronn, M., Meyermann, R., Schluessener, H. J., "Connective Tissue Growth Factor is Expressed by a Subset of Reactive Astrocytes in Human Cerebral Infarction," Neuropathology and Applied. Neurobiology 26(5):434-440 (2000)	
	C3	Schwab, J. M., Beschorner, R., Nguyen, T. D., Meyermann, R., Schluessener, H. J., "Differential Cellular Accumulation of Connective Tissue Growth Factor Defines a Subset of Reactive Astrocytes, Invading Fibroblasts, and Endothelial Cells Following Central Nervous System Injury in	
	C4	Shepard et al., "Delayed Secondary Glucocorticoid Responsiveness of MYOC in Human Trabecular Meshwork Cells", IOVS 42:3173-3181 (2001)	
	C5	Strong, N. P., "How optometrists screen for glaucoma: A survey", Ophthal. Physiol. Opt., 12:3-7 (1992)	
	C6	Vaughan, D. et al., In: GENERAL OPHTHALMOLOGY, Appleton & Lange, Norwalk, Conn., pp. 213-230 (1992)	
	C7	Wang et al., "Optimal procedure for extracting RNA from human ocular tissues and expression profiling of the congenital glaucoma gene FOXC1 using quantitative RT-PCR", Mol. Vis. 7:89-94 (2001)	
	C8	Willson, T. M. et al., "The PPARs: from orphan receptors to drug discovery" J MED CHEM 43(4):527-550 (2000)	
	C9	Woodgett, J. R., "Judging a protein by more than its name: GSK-3" SCIENCE'S STKE 2001(100):1-11 (2001)	
▼	C10	Zaharevitz, D. W. et al., "Discovery and initial characterization of the paullones, a novel class of small-molecule inhibitors of cyclin-dependent kinases" CANCER RES 59(11):2566-2569 (1999)	


Examiner Signature	/Ruth Davis/	Date Considered	02/26/2007
--------------------	--------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



10 Res'd P01/P10 31 MAR 2005

PTO/SB/08A (08-03)

Approved for use through 07/31/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

She

1

10

1

Complete if Known

Application Number	10/510,585
Filing Date	8 October 2004
First Named Inventor	Debra FLEENOR et al.
Art Unit	
Examiner Name	

Sh

1

Attorney Docket Number

2354 USE

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
RD		WO 00/30628 A2	06/02/2000	Genetech, Inc.		
RD		WO 01/25226 A1	04/12/2001	Bethesda Pharm.		
RD		WO 02/13812 A1	02/21/2002	Pershadsingh		
RD		WO 03/049773 A1	06/19/03	Fibrogen, Inc.		

**Examiner
Signature**

/Ruth Davis/

Date
Considered

02/26/2007

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO		Complete If Known		
		<i>Application Number</i>	10/510,585	
		<i>Filing Date</i>	October 8, 2004	
		<i>First Named Inventor</i>	FLEENOR	
		<i>Art Unit</i>	1651	
		<i>Examiner Name</i>	NYA	
Sheet	2	of	2	<i>Attorney Docket Number</i>
(Use as many sheets as necessary)				

NON PATENT LITERATURE DOCUMENTS

Examiner Signature	/Ruth Davis/	Date Considered	02/26/2007
-----------------------	--------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.